Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) traditionally follows a fixed initiation sequence.
• This conventional approach may not optimize treatment effectiveness or patient tolerability.
• The order of drug discovery does not necessarily correlate with optimal sequencing for patient benefit.

Purpose of the Study:

• To review and advocate for flexible sequencing of GDMT in HFrEF.
• To highlight the importance of individualized treatment strategies based on patient-specific factors.
• To emphasize the benefit of achieving partial doses of all foundational HFrEF therapies.

Main Methods:

• Literature review of current GDMT practices and evidence.
• Analysis of GDMT sequencing in special patient populations.
• Discussion of drug interactions and tolerance-building strategies.

Main Results:

• The effectiveness and tolerability of GDMT agents are not solely dependent on their discovery order.
• Flexible GDMT sequencing is beneficial for patients with comorbidities like bradycardia, chronic kidney disease, and atrial fibrillation.
• Initiating certain GDMT medications can improve tolerance to others.
• Attaining sub-maximal doses of all four pillars of GDMT yields better outcomes than maximizing only a subset of therapies.

Conclusions:

• Flexible GDMT sequencing in HFrEF should be considered, especially in complex patient populations.
• Individualized treatment approaches are superior to rigid protocols for optimizing HFrEF management.
• The goal of comprehensive GDMT, even at partial doses, is paramount for improving patient outcomes.